⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344283 | 0.82 | — | — | |
| SCHEMBL22417649 | 0.82 | — | — | |
| SCHEMBL13273709 | 0.79 | — | — | |
| SCHEMBL24062637 | 0.76 | — | — | |
| SCHEMBL24720970 | 0.64 | — | — | |
| SCHEMBL18716250 | 0.64 | — | — | |
| SCHEMBL2236437 | 0.57 | — | — | |
| SCHEMBL6899229 | 0.48 | — | — | |
| SCHEMBL3622480 | 0.48 | — | — | |
| SCHEMBL2404097 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689376-B2 | Substituted-3H-imidazo [4,5-c] pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-20190031655-A1 | Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics | Stingray Therapeutics, Inc. | 2019-01-31 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| WO-2015089143-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-18 | — | — | WO | disclosed |
| EP-2143727-B1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8288613-B2 | Lignan hydroxylase | SUNTORY HOLDINGS LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8236807-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100015092-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | NAKAJIMA SUANNE | 2010-01-21 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2004093798-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-11-04 | — | — | WO | disclosed |